BIOLINERX Ltd/S (NASDAQ:BLRX) has been assigned a $4.00 target price by research analysts at HC Wainwright in a note issued to investors on Tuesday, August 7th. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 330.11% from the company’s previous close.
BLRX has been the topic of a number of other reports. ValuEngine upgraded BIOLINERX Ltd/S from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Zacks Investment Research upgraded BIOLINERX Ltd/S from a “hold” rating to a “buy” rating and set a $1.00 price target on the stock in a research note on Friday, May 25th. Finally, MED began coverage on BIOLINERX Ltd/S in a research note on Wednesday, August 1st. They issued a “market perform” rating on the stock. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $2.50.
NASDAQ:BLRX traded up $0.01 during midday trading on Tuesday, reaching $0.93. The company had a trading volume of 414,800 shares, compared to its average volume of 396,130. The firm has a market cap of $94.51 million, a PE ratio of -3.41 and a beta of 0.50. BIOLINERX Ltd/S has a 12-month low of $0.78 and a 12-month high of $1.34.
About BIOLINERX Ltd/S
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Read More: Do closed-end mutual funds pay dividends?
Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.